Drug Name |
Pimecrolimus |
Drug ID |
BADD_D01773 |
Description |
Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema). |
Indications and Usage |
For treatment of mild to moderate atopic dermatitis. |
Marketing Status |
approved; investigational |
ATC Code |
D11AH02 |
DrugBank ID |
DB00337
|
KEGG ID |
D05480
|
MeSH ID |
C117268
|
PubChem ID |
6447131
|
TTD Drug ID |
D0Z4UN
|
NDC Product Code |
55486-1585; 68682-112; 62227-004; 68254-0014; 0187-5102; 0591-2944; 62227-024; 65727-045; 0187-5101; 53296-0115; 0187-5100; 68682-110; 68462-609; 68682-111; 51552-1620; 16436-0115; 0187-5103 |
UNII |
7KYV510875
|
Synonyms |
pimecrolimus | 33-epi-chloro-33-desoxyascomycin | SDZ ASM 981 | SDZ-ASM-981 | ASM 981 | Elidel |